EcstasyData: After several re-examinations of this sample and comparisons to new databases, as of July 26, 2015, this sample is confirmed to be 5-APDB. This sample is NOT 5- or 6-MAPB
The rest of the comments are mostly for tracking the history of identifying the contents of this sample.
Initially, the lab's GC/MS technique could not differentiate between 6-MAPB and 5-MAPB. The substance was tentatively identified as being either 6-MAPB or 5-MAPB.
Erowid ordered several lab standards for similar substances that the lab used to calibrate their GC/MS equipment to better be able to identify this class of substances. After examining these new chemical standards, the lab changed its identification of this sample 6-APDB.
This identification is still tentative because we have not yet been able to acquire a lab standard for 6-APDB. However the lab is confident that the sample submitted is NOT an -MAPB or -APB.
The lab wrote:
This sample (40900034, 6-MAPB ASK14) is neither 5- or 6-MAPB, but is closer to the to 6-APDB. These compounds are listed as there IUPAC names on SWGDrug library spectra which makes it a little tougher to identify. IUPAC names are long, not practical for the streets. So I can't tell for sure what street names refer to which formally-named chemical. Regardless, each of these chemicals are very, very similar in structure and in their mass spectrum finger prints. As of now, with the help of the new standards and more thorough Internet searching, the spectra more resembles 6-APDB.
We have ordered more analytical standards and will continue to try to determine whether we can differentiate between this series of very, very similar MDMA-analogs.
In July, 2015, we received word from a visitor that they had a confirmed sample of 6-APDB and their marquis reagent color was very different from this sample. The marquis spot color they saw was a dark purple.
Send in a sample for testing
DrugsData tests all psychoactive drugs including ecstasy tablets, powders, research chemicals, novel pschoactive substances, and other drugs through our licensed laboratory. Ecstasy/Molly tablets cost $100. Recreational drug powder/crystal/blotter costs $100. Pharmaceuticals, supplements and all others cost $150 per analysis.
Should the public have access to independent analysis of the products they consume?
The vast majority of analyses of over-the-counter, prescription, and recreational drugs are performed in secret with no independent oversite or review. No other historical record, free from politically-controlled agencies, is currently available in North America nor most other parts of the world.
DrugsData, a project of Erowid Center, needs the support of professionals, students, parents, individuals with means, and small foundations for a total yearly budget of around $120,000 USD. Erowid Center's general budget and the co-pays we require fund most of this cost.
EcstasyData: After several re-examinations of this sample and comparisons to new databases, as of July 26, 2015, this sample is confirmed to be 5-APDB. This sample is NOT 5- or 6-MAPB
Initially, the lab's GC/MS technique could not differentiate between 6-MAPB and 5-MAPB. The substance was tentatively identified as being either 6-MAPB or 5-MAPB.
Erowid ordered several lab standards for similar substances that the lab used to calibrate their GC/MS equipment to better be able to identify this class of substances. After examining these new chemical standards, the lab changed its identification of this sample 6-APDB.
This identification is still tentative because we have not yet been able to acquire a lab standard for 6-APDB. However the lab is confident that the sample submitted is NOT an -MAPB or -APB.
The lab wrote: